Y Intercept Hong Kong Ltd Takes Position in Collegium Pharmaceutical, Inc. $COLL

Y Intercept Hong Kong Ltd purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,748 shares of the specialty pharmaceutical company’s stock, valued at approximately $686,000. Y Intercept Hong Kong Ltd owned approximately 0.06% of Collegium Pharmaceutical as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after purchasing an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Collegium Pharmaceutical by 65.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after acquiring an additional 518,721 shares during the last quarter. Millennium Management LLC grew its stake in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Collegium Pharmaceutical by 161.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock valued at $23,692,000 after purchasing an additional 316,109 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Collegium Pharmaceutical by 897.2% during the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after purchasing an additional 242,310 shares during the period.

Collegium Pharmaceutical Stock Down 1.2%

COLL stock opened at $34.82 on Tuesday. The business’s 50-day moving average price is $34.71 and its 200-day moving average price is $38.64. The stock has a market cap of $1.13 billion, a P/E ratio of 17.07 and a beta of 0.73. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical, Inc. has a twelve month low of $29.19 and a twelve month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. During the same period in the prior year, the firm posted $1.49 EPS. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. Zacks Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.